New cancer clinical trial: Assessment of the Immunogenicity of Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer

Published on: April 27, 2018 at 12:00PM
Condition:   Breast Cancer
Interventions:   Drug: Lupin's Pegfilgrastim;   Drug: Neulasta®
Sponsor:   Lupin Ltd.
Recruiting
https://ift.tt/2vXU2Jn